Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can early UVB and steroids stop vitiligo in its tracks?

NCT ID NCT04843059

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether starting treatment early with UVB light therapy and low-dose steroids can stop vitiligo from spreading and improve skin color return. 51 people with different stages of vitiligo were treated for 6 months. Researchers took skin samples to see how immune cells changed. The goal is to find a way to prevent relapses, which happen in up to half of patients after repigmentation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
narrowband UVB light therapy and oral steroids (methylprednisolone)
What this could lead to
If successful, this approach could lead to better repigmentation and fewer relapses for people with vitiligo by targeting the immune cells in the skin early.
What could go wrong
This is a small, early-stage study (51 people) without a placebo group, so results may not apply to everyone. Steroids and UVB have side effects, and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

51 people

The number who actually took part.

Started

Jun 2021

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Patients with non-segmental vitiligo. 3 groups of patients will be selected: * Patients with a long-lasting disease (more than 2 years) and no new or growing lesion since at least 2 years * Patients with a long-lasting disease (more than 2 years) and with at least one new lesion since less than 6 months * Patients developing for the first-time vitiligo lesions with all the lesions no older than 6 months 2. ≥ 18 and \<35 years to have a homogeneous distribution of age between the three groups, as 80% of vitiligo cases start before the age of 30. 3\. Patient with at least one lesion of more than 2 cm² not located on the face, hands or feet. 4\. Patient needing a treatment with oral minipulses of steroids and phototherapy 5. For women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed. 6\. Affiliation to a social security system 7. Signed informed consent Exclusion Criteria: * 1\. Pregnant or breast-feeding women. Or women who plan to get pregnant during the study duration. 2\. Segmental or mixed vitiligo 3. Vitiligo located only on face, hands and feet 4. Exposure to solar or artificial UV during the months before inclusion 5. Concomitant use of topical or systemic immunosuppressive medication or steroids 6. Patients suffering from photodermatosis or taking photosensitive drugs 7. Personal history of skin cancer. 8. Patients with diabetes, high blood pressure, osteoporosis or any other contra-indication to the use of systemic steroids. 9\. Vulnerable people: pregnant or breast-feeding women, minors, adult under guardianship or deprived of freedom 10. Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, 33440, France

  • CHU de Nice

    Nice, alpes maritimes, 06001, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.